Role of metabolic syndrome components in HIV-associated sensory neuropathy.

TitleRole of metabolic syndrome components in HIV-associated sensory neuropathy.
Publication TypeJournal Article
Year of Publication2009
AuthorsAnces, BM, Vaida, F, Rosario, D, Marquie-Beck, J, Ellis, RJ, Simpson, DM, Clifford, DB, McArthur, JC, Grant, I, J McCutchan, A
Corporate AuthorsCNS HIV Antiretroviral Therapy Effects Research (CHARTER) Metabolic Study Group
JournalAIDS
Volume23
Issue17
Pagination2317-22
Date Published2009 Nov 13
ISSN1473-5571
KeywordsAdult, Antiretroviral Therapy, Highly Active, CHARTER, Female, HIV Infections, Humans, Internal, Male, Metabolic Syndrome, Middle Aged, Peripheral Nervous System Diseases, Prospective Studies, Sensation Disorders
Abstract

OBJECTIVES: Sensory neuropathy is a common peripheral nerve complication of HIV infection and highly active antiretroviral therapy. Metabolic syndrome (MetS), a cluster of risk factors for atherosclerosis and microvascular disease, is associated with sensory neuropathy in HIV-uninfected (HIV-negative) persons. We examined whether MetS or its components predispose individuals to HIV-associated sensory neuropathy (HIV-SN).DESIGN: From a prospective multicenter cohort of 1556 HIV-positive patients, a subgroup (n = 130) with fasting laboratory tests and sensory neuropathy assessment was selected.METHODS: Sensory neuropathy was defined by symmetrically decreased reflexes or sensation loss in the legs. MetS was defined by presence of at least three risk factors: mean arterial pressure of at least 100 mmHg; triglycerides (TRGs) of at least 150 mg/dl and high-density lipoprotein cholesterol of less than 40 mg/dl for male patients, less than 50 mg/dl for female patients; body mass index of more than 25 kg/m; plasma glucose (GLU) of at least 100 mg/dl and self-reported diabetes mellitus type 2. Multivariate logistic regression examined the association between HIV-SN and MetS.RESULTS: After controlling for HIV-SN risk factors such as age, CD4 current, length of HIV infection, use of dideoxynucleoside reverse transcriptase inhibitors and protease inhibitors, MetS was not associated with HIV-SN (P = 0.72). However, when each MetS component was assessed, elevated TRG was a significant risk factor for HIV-SN. From the larger cohort, both diabetes mellitus type 2 (odds ratio = 1.4, P < 0.01) and elevated TRG (odds ratio = 1.4, P = 0.01) were risk factors for HIV-SN.CONCLUSION: The risk of HIV-SN was increased for diabetes mellitus type 2 and elevated TRG but not for other MetS components. Both increase the risk of sensory neuropathy in HIV-populations, but the mechanism(s) remains unclear.

DOI10.1097/QAD.0b013e328332204e
Alternate JournalAIDS
PubMed ID19823068
PubMed Central IDPMC2896813
Grant ListK23 MH081786-03 / MH / NIMH NIH HHS / United States
K23 MH081786-01 / MH / NIMH NIH HHS / United States
K23 MH081786 / MH / NIMH NIH HHS / United States
K23 MH081786-04 / MH / NIMH NIH HHS / United States
K23 MH081786-02 / MH / NIMH NIH HHS / United States